Sensititre Plate Guide Booklet EN PDF
Sensititre Plate Guide Booklet EN PDF
Plate Guide
for Antimicrobial Susceptibility Testing
Table of Contents
Introduction 3
Quality Control 57
Custom Capabilities 58
Glossary 61
INTRODUCTION
“Antimicrobial resistance is a
global health emergency that will
seriously jeopardize progress in
modern medicine.” ¹
– Dr. Tedros Adhanom Ghebreyesus
Director-General, WHO
¹World Health Organization. (2017, September 20). The world is running out of antibiotics, WHO report confirms [Press Release].
Retrieved from: http://www.who.int/mediacentre/news/releases/2017/running-out-antibiotics/en/
3
THE THERMO SCIENTIFIC SENSITITRE SYSTEM
To effectively combat antimicrobial resistance, you need the right antimicrobials at the right dose.
To improve patient care outcomes, you need faster, more reliable AST devices. Whether you prefer manual
or automated solutions, you’ll find the right fit for your specific susceptibility testing needs and volume
requirements with the Thermo Scientific Sensititre ID/AST System. Customizable testing options are
also available, and all solutions are designed to maximize accuracy and reproducibility.
The Sensititre System utilizes both in vitro diagnostic (IVD) and research use only (RUO), 96-well microtitre
plates. With over 240 antimicrobials available in extended dilution ranges on a wide variety of formats, the
Sensititre System allows you to consolidate confirmatory tests while meeting FDA, CLSI and EUCAST
breakpoint requirements.
Thermo Scientific™
Sensititre™ ARIS™
2X Instrument†–a
fully automated,
benchtop incubating
and reading system
that facilitates efficient workflow,
with the benefits of Expert System
software and LIS connectivity.
†
Not available in Europe.
4
THE VALUE OF A TRUE MIC FOR AST
Current AST methods are based on assessing the ability of an antimicrobial to inhibit bacterial growth.
The minimum inhibitory concentration (MIC) is the level of antimicrobic required to achieve inhibition
against the tested pathogen. However, some AST systems calculate the MIC value by extrapolating
growth curves and applying dedicated algorithms.
The Sensititre System generates true MIC results based on actual growth of the organism. A true
MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the
organism is against a particular drug, and the exact point at which the isolate becomes resistant.
When comparing your MIC results against the latest clinical breakpoints from EUCAST and CLSI,
you can trust the value of a true MIC to deliver the accuracy required for optimal patient outcomes,
and to track emerging resistance.
5
HUMAN
Fastidious Yeast
6
Human
Intended Use
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 1 μl*, 10 μl**, or 30 μl*** the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
of suspension into MHB Multi-Channel Pipette for 18-24 hours Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A AMI TGC LEVO DOR ETP IMI MERO FAZ TAZ AZT FEP AXO AMI Amikacin
8 1 1 0.5 0.25 0.5 0.5 1 1 1 4 0.5 P/T4 Piperacillin / Tazobactam constant 4
TGC Tigecyline
TIM2 Ticarcillin / Clavulanic acid constant 2
B AMI TGC LEVO DOR ETP IMI MERO FAZ TAZ AZT FEP AXO
16 2 2 1 0.5 1 1 2 2 2 8 1 LEVO Levofloxacin
NIT Nitrofurantoin
TET Tetracycline
C AMI TGC LEVO DOR ETP IMI MERO FAZ TAZ AZT FEP AXO DOR Doripenem
32 4 4 2 1 2 2 4 4 4 16 2
MIN Minocycline
ETP Ertapenem
P/T4 TGC LEVO DOR ETP IMI MERO FAZ TAZ AZT FEP AXO SXT Trimethoprim / Sulfamethoxazole
D
8/4 8 8 4 2 4 4 8 8 8 32 4 IMI Impenem
PIP Piperacillin
MERO Meropenem
E P/T4 TIM2 NIT MIN ETP IMI MERO FAZ TAZ AZT CIP AXO
16/4 8/2 32 1 4 8 8 16 16 16 0.5 8 GEN Gentamicin
FAZ Ceftazidime
TOB Tobramycin
P/T4 TIM2 NIT MIN ETP PIP GEN TOB A/S2 AMP CIP AXO TAZ Ceftazidime
F 32/4 16/2 64 2 8 16 4/2
2 2 8 1 16 A/S2 Ampicillin / Sulbactam 2:1 ratio
AZT Aztreonam
P/T4 TIM2 TET MIN SXT PIP A/S2 AMP CIP AXO AMP Amicillin
G GEN TOB
64/4 32/2 4 4 2/38 32 4 4 8/4 16 2 32 FEP Cefepime
CIP Ciprofloxacin
AXO Ceftriaxone
P/T4 TIM2 TET MIN SXT PIP GEN TOB A/S2 POS POS POS POS Positive control
H
128/4 64/2 8 8 4/76 64 8 8 16/8
*For Proteus spp. **For Enterobacteriaceae and Non-Enterobacteriaceae. ***For aid in detection of resistance mechanisms for Enterobacteriaceae and Non-Enterobacteriaceae. †Not available in Europe.
7
Human
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 1 μl*, 10 μl**, or 30 μl*** the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
of suspension into MHB Multi-Channel Pipette for 18-24 hours Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A AMI TGC LEVO DOR ETP IMI MERO FAZ TAZ AZT FEP AXO AMI Amikacin
8 1 1 0.5 0.25 1 0.5 1 1 1 2 0.5 AMP Ampicillin
A/S2 Ampicillin / Sulbactam 2:1 ratio
AZT Aztreonam
B AMI TGC LEVO DOR ETP IMI MERO FAZ TAZ AZT FEP AXO
16 2 2 1 0.5 2 1 2 2 2 4 1 FAZ Cefazolin
FEP Cefepime
TAZ Ceftazidime
C AMI TGC LEVO DOR ETP IMI MERO FAZ TAZ AZT FEP AXO CZA Ceftazidime / Avibactam
32 4 4 2 1 4 2 4 4 4 8 2
C/T Ceftolozane / Tazobactam 4
AXO Ceftriaxone
P/T4 TGC LEVO DOR ETP IMI MERO FAZ TAZ AZT FEP AXO CIP Ciprofloxacin
D
8/4 8 8 4 2 8 4 8 8 8 16 4 DOR Doripenem
ETP Ertapenem
GEN Gentamicin
E P/T4 C/T NIT MIN ETP CZA MERO FAZ TAZ AZT CIP AXO
IMI Imipenem
16/4 2/4 32 1 4 2/4 8 16 16 16 0.5 8
LEVO Levofloxacin
MERO Meropenem
P/T4 C/T NIT MIN ETP CZA GEN TOB A/S2 AMP CIP AXO MIN Minocycline
F 32/4 4/4 64 2 8 4/4 4/2
2 2 8 1 16 NIT Nitrofurantoin
P/T4 Piperacillin / Tazobactam constant 4
TET Tetracycline
G P/T4 C/T TET MIN SXT CZA GEN TOB A/S2 AMP CIP AXO
64/4 8/4 4 4 2/38 8/4 4 4 8/4 16 2 32 TGC Tigecycline
TOB Tobramycin
SXT Trimethoprim / Sulfamethoxazole
P/T4 C/T TET MIN SXT CZA GEN TOB A/S2 POS POS POS POS Positive control
H
128/4 16/4 8 8 4/76 16/4 8 8 16/8
*For Proteus spp. **For Enterobacteriaceae and Non-Enterobacteriaceae. ***For aid in detection of resistance mechanisms for Enterobacteriaceae and Non-Enterobacteriaceae. †Not available in Europe.
8
Human
Intended Use
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 1 μl*, 10 μl**, or 30 μl*** the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
of suspension into MHB Multi-Channel Pipette for 18-24 hours Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A AMI AZT SXT FEP LEVO CIP MERO DOR DOR DOR DOR DOR AMI Amikacin
4 2 0.5/9.5 2 1 0.25 1 0.12 0.25 0.5 1 2 TIM2 Ticarcillin / Clavulanic acid constant 2
AZT Aztreonam
P/T4 Piperacillin / Tazobactam constant 4
B AMI AZT SXT FEP LEVO CIP MERO COL COL COL COL COL
8 4 1/19 4 2 0.5 2 0.25 0.5 1 2 4 SXT Trimethoprim / Sulfamethoxazole
GEN Gentamicin
FEP Cefepime
C AMI AZT SXT FEP LEVO CIP MERO POL POL POL POL POL TOB Tobramycin
16 8 2/38 8 4 1 4 0.25 0.5 1 2 4
LEVO Levofloxacin
DOX Doxycycline
AMI AZT SXT FEP LEVO CIP MERO TAZ TAZ TAZ TAZ TAZ CIP Ciprofloxacin
D
32 16 4/76 16 8 2 8 1 2 4 8 16 MIN Minocycline
MERO Meropenem
FOT Cefotaxime
E TIM2 P/T4 GEN TOB DOX MIN FOT FOT FOT FOT FOT FOT
TGC Tigecycline
16/2 8/4 1 1 2 2 1 2 4 8 16 32
ETP Ertapenem
IMI Imipenem
TIM2 P/T4 GEN TOB DOX MIN TGC TGC TGC TGC TGC TGC DOR Doripenem
F 32/2 16/4 2 2 4 4 1
0.25 0.5 2 4 8 COL Colistin
POL Polymixin B
TAZ Ceftazidime
G TIM2 P/T4 GEN TOB DOX MIN ETP ETP ETP ETP ETP POS
64/2 32/4 4 4 8 8 0.25 0.5 1 2 4 POS Positive control
TIM2 P/T4 GEN TOB DOX MIN IMI IMI IMI IMI POS POS
H
128/2 64/4 8 8 16 16 1 2 4 8
*For Proteus spp. **For Enterobacteriaceae and Non-Enterobacteriaceae. ***For aid in detection of resistance mechanisms for Enterobacteriaceae and Non-Enterobacteriaceae. †Not available in Europe.
9
Meet the latest
antimicrobials
on our new
single-drug plate
Indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the Sensititre Delafloxacin
Plate provides true MIC results that meet both FDA and CLSI requirements in an off-the-shelf, standard format, as well as:
Not all products are available for sale in all territories. Please inquire.
10
Human
Intended Use
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in a Manually read with
using the Nephelometer, the suspension using non-CO2 incubator or Sensititre Vizion or
Mix 1 μl*, 10 μl**, or 30 μl*** the Sensititre AIM or Sensititre ARIS 2X† Sensititre Manual Viewbox
of suspension into MHB Multi-Channel Pipette for 18-24 hours
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A DLX POS DLX POS DLX POS DLX POS DLX POS DLX POS
0.004 0.004 0.004 0.004 0.004 0.004 DLX Delafloxacin
POS Positive control
E DLX DLX DLX DLX DLX DLX DLX DLX DLX DLX DLX DLX
0.06 8 0.06 8 0.06 8 0.06 8 0.06 8 0.06 8
DLX DLX DLX DLX DLX DLX DLX DLX DLX DLX DLX DLX
F 0.12 4 0.12 4 0.12 4 0.12 4 0.12 4 0.12 4
G DLX DLX DLX DLX DLX DLX DLX DLX DLX DLX DLX DLX
0.25 2 0.25 2 0.25 2 0.25 2 0.25 2 0.25 2
DLX DLX DLX DLX DLX DLX DLX DLX DLX DLX DLX DLX
H 0.5 1 0.5 1 0.5 1 0.5 1 0.5 1 0.5 1
*For Proteus spp. **For Enterobacteriaceae and Non-Enterobacteriaceae. ***For aid in detection of resistance mechanisms for Enterobacteriaceae and Non-Enterobacteriaceae. †Not available in Europe.
11
Meet the latest
antimicrobials
on our new
dual-drug plate
Mitigating carbepenem resistance and expanding patient treatment options requires faster access to an AST device
with the most up-to-date antimicrobials. Discover our latest standard format addition for Gram negative organisms
with the Sensititre Meropenem/Vaborbactam MEROVAB plate.
A dual component drug granted fast-track approval by the FDA, meropenem/vaborbactam is indicated for the treatment
of serious Gram negative infections, such as complicated urinary tract infections. The Sensititre Meropenem/Vaborbactam
Plate provides true MIC results that meet both FDA and CLSI requirements in an off-the-shelf, standard format, as well as:
Not all products are available for sale in all territories. Please inquire.
12
Human
Sensititre Meropenem/Vaborbactam
MEROVAB Plate
Intended Use
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in a Manually read with
using the Nephelometer, the suspension using non-CO2 incubator or Sensititre Vizion or
Mix 1 μl*, 10 μl**, or 30 μl*** the Sensititre AIM or Sensititre ARIS 2X† Sensititre Manual Viewbox
of suspension into MHB Multi-Channel Pipette for 18-24 hours
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A MEV MERO MERO POS MEV MERO MERO POS MEV MERO MERO POS
0.008/8 1 0.004 0.008/8 1 0.004 0.008/8 1 0.004 MERO Meropenem
MEV Meropenem / Vaborbactam
POS Positive control
B MEV MERO MERO MEV MERO MERO MEV MERO MERO
0.015/8 2 0.008 0.015/8 2 0.008 0.015/8 2 0.008
*For Proteus spp. **For Enterobacteriaceae and Non-Enterobacteriaceae. ***For aid in detection of resistance mechanisms for Enterobacteriaceae and Non-Enterobacteriaceae. †Not available in Europe.
13
Human
Intended Use
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 1 μl*, 10 μl**, or 30 μl*** the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
of suspension into MHB Multi-Channel Pipette for 18-24 hours Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A AMI GEN TOB CIP SXT AZT FEP COL COL COL COL COL AMI Amikacin
4 1 1 0.06 0.5/9.5 2 2 0.25 0.5 1 2 4 DOX Doxycycline
GEN Gentamicin
MIN Minocycline
B AMI GEN TOB CIP SXT AZT FEP POL POL POL POL POL
8 2 2 0.12 1/19 4 4 0.25 0.5 1 2 4 TOB Tobramycin
TGC Tigecycline
CIP Ciprofloxacin
C AMI GEN TOB CIP SXT AZT FEP TAZ TAZ TAZ TAZ TAZ SXT Trimethoprim / Sulfamethoxazole
16 4 4 0.25 2/38 8 8 1 2 4 8 16
LEVO Levofloxacin
AZT Aztreonam
AMI GEN TOB CIP SXT AZT FEP FOT FOT FOT FOT FOT IMI Imipenem
D
32 8 8 0.5 4/76 16 16 2 4 8 16 32 FEP Cefepime
MERO Meropenem
COL Colistin
E DOX MIN TGC CIP LEVO IMI MERO A/S2 A/S2 A/S2 A/S2 A/S2
POL Polymixin B
2 2 0.25 1 1 1 1 4/2 8/4 16/8 32/16 64/32
TAZ Ceftazidime
FOT Cefotaxime
DOX MIN TGC CIP LEVO IMI MERO DOR DOR DOR DOR POS A/S2 Ampicillin / Sulbactam 2:1 ratio
F 4 2 0.5 2 2 2 1
2 0.5 2 4 DOR Doripenem
P/T4 Piperacillin / Tazobactam constant 4
TIM2 Ticarcillin / Clavulanic acid constant 2
G DOX MIN TGC TGC LEVO IMI MERO P/T4 P/T4 P/T4 P/T4 POS
8 8 1 4 4 4 4 8/4 16/4 32/4 64/4 POS Positive control
DOX MIN TGC TGC LEVO IMI MERO TIM2 TIM2 TIM2 TIM2 POS
H
16 16 2 8 8 8 8 16/2 32/2 64/2 128/2
*For Proteus spp. **For Enterobacteriaceae and Non-Enterobacteriaceae. ***For aid in detection of resistance mechanisms for Enterobacteriaceae and Non-Enterobacteriaceae. †Not available in Europe.
14
Human
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in Manually read with
using the Nephelometer, the suspension using a non-CO2 incubator or Sensititre Vizion or
Mix 1 μl*, 10 μl**, or 30 μl*** the Sensititre AIM or Sensititre ARIS 2X† Sensititre Manual Viewbox
of suspension into MHB Multi-Channel Pipette for 18-24 hours
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A MERO MERO MERO MERO MERO MERO MERO MERO AMI AMI AMI AMI
0.12 0.25 0.5 1 2 4 8 16 4 8 16 32 MERO Meropenem
GEN Gentamicin
CIP Ciprofloxacin
B GEN GEN GEN GEN GEN AZT AZT AZT AZT AZT AZT AZT AUGC Amoxicillin / Clavulanic acid constant 2
0.5 1 2 4 8 0.5 1 2 4 8 16 32 COL Colistin
TGC Tigecycline
TAZ Ceftazidime
C CIP CIP CIP CIP CIP CIP P/T4 P/T4 P/T4 P/T4 P/T4 P/T4
0.06 0.12 0.25 0.5 1 2 1/4 2/4 4/4 8/4 16/4 32/4 IMI Imipenem
AZT Aztreonam
C/T Ceftolozane / Tazobactam 4
D AUGC AUGC AUGC AUGC AUGC C/T C/T C/T C/T C/T C/T C/T SXT Trimethoprim / Sulfamethoxazole
4/2 8/2 16/2 32/2 64/2 0.5/4 1/4 2/4 4/4 8/4 16/4 32/4
P/T4 Piperacillin / Tazobactam constant 4
FOT Cefotaxime
E COL COL COL COL COL COL FOT FOT FOT FOT FOT TOB CZA Ceftazidime / Avibactam
0.25 0.5 1 2 4 8 0.5 1 2 4 8 1 ETP Ertapenem
AMI Amikacin
TOB Tobramycin
TGC TGC TGC TGC TGC SXT SXT SXT SXT TOB TOB TOB
F 0.25 0.5 1 2 4 1/19 2/38 4/76 8/152 2 4 8 POS Positive control
G TAZ TAZ TAZ TAZ TAZ TAZ CZA CZA CZA CZA CZA CZA
0.5 1 2 4 8 16 0.5/4 1/4 2/4 4/4 8/4 16/4
IMI IMI IMI IMI IMI IMI ETP ETP ETP ETP ETP POS
H
0.5 1 2 4 8 16 0.12 0.25 0.5 1 2
*For Proteus spp. **For Enterobacteriaceae and Non-Enterobacteriaceae. ***For aid in detection of resistance mechanisms for Enterobacteriaceae and Non-Enterobacteriaceae. †Not available in Europe.
15
Human
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and
o
measure a 0.5 McFarland 50 μl volume per well incubate at 34-36 C in Manually read with
using the Nephelometer, of the suspension using a non-CO2 incubator or Sensititre Vizion or
Mix 1 μl*, 10 μl**, or 30 μl*** the Sensititre AIM or Sensititre ARIS 2X† Sensititre Manual Viewbox
of suspension into MHB Multi-Channel Pipette for 18-24 hours
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A COL P/T4 C/T POS COL P/T4 C/T POS COL P/T4 C/T POS
0.25 4/4 4/4 0.25 4/4 4/4 0.25 4/4 4/4 COL Colistin
P/T4 Piperacillin / Tazobactam constant 4
C/T Ceftolozane / Tazobactam 4
B COL P/T4 C/T MERO COL P/T4 C/T MERO COL P/T4 C/T MERO CZA Ceftazidime / Avibactam
0.5 8/4 8/4 0.25 0.5 8/4 8/4 0.25 0.5 8/4 8/4 0.25 MERO Meropenem
POS Positive control
C COL P/T4 CZA MERO COL P/T4 CZA MERO COL P/T4 CZA MERO
1 16/4 1/4 0.5 1 16/4 1/4 0.5 1 16/4 1/4 0.5
D COL P/T4 CZA MERO COL P/T4 CZA MERO COL P/T4 CZA MERO
2 32/4 2/4 1 2 32/4 2/4 1 2 32/4 2/4 1
E COL C/T CZA MERO COL C/T CZA MERO COL C/T CZA MERO
4 0.25/4 4/4 2 4 0.25/4 4/4 2 4 0.25/4 4/4 2
COL C/T CZA MERO COL C/T CZA MERO COL C/T CZA MERO
F 8 0.5/4 8/4 4 8 0.5/4 8/4 4 8 0.5/4 8/4 4
G P/T4 C/T CZA MERO P/T4 C/T CZA MERO P/T4 C/T CZA MERO
1/4 1/4 16/4 8 1/4 1/4 16/4 8 1/4 1/4 16/4 8
P/T4 C/T MERO MERO P/T4 C/T MERO MERO P/T4 C/T MERO MERO
H
2/4 2/4 0.12 16 2/4 2/4 0.12 16 2/4 2/4 0.12 16
*For Proteus spp. **For Enterobacteriaceae and Non-Enterobacteriaceae. ***For aid in detection of resistance mechanisms for Enterobacteriaceae and Non-Enterobacteriaceae. †Not available in Europe.
16
Human
Intended Use
0.5 McFarland Standard Sensititre Mueller Hinton Broth IVD Autoread or Manual
w/Lysed Horse Blood - Sensititre ARIS 2X† (V3090)
(E1041) manual read (CP112-10) or FDA
Sensititre OptiRead (V3030)
Sensititre Mueller Hinton Sensititre Mueller Hinton Broth [US] Sensititre Vizion (V2021)
w/Lysed Horse Blood -
Broth 5 ml (T346205) autoread (CP11410) Sensititre Manual Viewbox (V4007)
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 100 μl volume per well incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, of the suspension using a non-CO2 incubator or or manually read with
Mix 100 μl of suspension the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
into MHB w/ LHB Tube Multi-Channel Pipette for 20-24 hours Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A ORI ORI ORI ORI ORI ORI ORI ORI ORI ORI ORI ORI
0.0005 0.001 0.002 0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 CLI Clindamycin
CPT Ceftaroline
DAL Dalbavancin
B TZD TZD TZD TZD TZD TZD TZD TZD TZD TZD TZD TZD DTS D Test
0.002 0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 ERY Erythromycin
LZD Linezoid
ORI Oritavancin
C CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT
0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 TLA Telavancin
TZD Tedizolid
VAN Vancomycin
D DAL DAL DAL DAL DAL DAL DAL DAL DAL DAL DAL DAL POS Positive control
0.001 0.002 0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2
E TLA TLA TLA TLA TLA TLA TLA TLA TLA TLA TLA TLA
0.001 0.002 0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2
CLI CLI CLI CLI ERY ERY ERY ERY ERY POS POS POS
H 0.12 0.25 0.5 1 0.25 0.5 1 2 4
†
Not available in Europe.
17
Human
Sensititre Streptococcus
species STP6F Plate
Intended Use
0.5 McFarland Standard Sensititre Mueller Hinton Broth IVD Autoread or Manual
w/Lysed Horse Blood - Sensititre ARIS 2X† (V3090)
(E1041) manual read (CP112-10) or FDA, CLSI
Sensititre OptiRead (V3030)
Sensititre Mueller Hinton Sensititre Mueller Hinton Broth [Worldwide] Sensititre Vizion (V2021)
w/Lysed Horse Blood -
Broth 5 ml (T346205) autoread (CP11410) Sensititre Manual Viewbox (V4007)
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 100 μl volume per well incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, of the suspension using a non-CO2 incubator or or manually read with
Mix 100 μl of suspension the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
into MHB w/ LHB Tube Multi-Channel Pipette for 20-24 hours Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A MXF MXF MXF MXF PEN PEN PEN PEN PEN PEN PEN PEN
1 2 4 8 0.03 0.06 0.12 0.25 0.5 1 2 4 MXF Moxifloxacin
LEVO Levofloxacin
TET Tetracycline
B LEVO LEVO LEVO LEVO MERO MERO MERO MERO AZI AZI AZI AZI FUR Cefuroxime
0.05 1 2 4 0.25 0.5 1 2 0.25 0.5 1 2 AXO Ceftriaxone
FOT Cefotaxime
DAP Daptomycin
C TET TET TET TET ETP ETP ETP ERY ETP ERY ERY ERY
1 2 4 8 0.5 1 2 4 0.25 0.5 1 2 CHL Chloramphenicol
PEN Penicillin
MERO Meropenem
D FUR FUR FUR FUR AUG2 AUG2 AUG2 AUG2 SXT SXT SXT SXT ETP Ertapenem
0.5 1 2 4 2/1 4/2 8/4 16/8 0.5/9.5 1/19 2/38 4/76
AUG2 Amoxicillin / Clavulanic acid 2:1 ratio
LAZD Linezolid
E AXO AXO AXO AXO AXO LZD LZD LZD LZD LZD VAN VAN CLI Clindamycin
0.12 0.25 0.5 1 2 0.25 0.5 1 2 4 0.5 1 FEP Cefepime
TGC Tigecycline
AZI Azithromycin
FOT FOT FOT FOT FOT FOT CLI CLI CLI CLI VAN VAN
F 0.12 0.25 0.5 1 2 4 0.12 0.25 0.5 1 2 4 ERY Erythromycin
SXT Trimethoprim / Sulfamethoxazole
VAN Vancomycin
G DAP DAP DAP DAP DAP DAP FEP FEP FEP FEP FEP POS POS Positive control
0.06 0.12 0.25 0.5 1 2 0.5 1 2 4 8
CHL CHL CHL CHL CHL CHL TGC TGC TGC TGC POS POS
H 1 2 4 8 16 32 0.015 0.03 0.06 0.12
†
Not available in Europe.
18
Human
Antimicrobial susceptibility plate for testing Streptococcus pneumoniae and Haemophilus influenzae isolates
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and
o
measure a 0.5 McFarland 100 μl volume per well incubate at 34-36 C in Manually read with
using the Nephelometer, Mix 50 μl* of the suspension using a non-CO2 incubator or Sensititre Vizion or
or 100 μl** of suspension into the Sensititre AIM or Sensititre ARIS 2X† Sensititre Manual Viewbox
HTM* or MHB w/ LHB Tube** Multi-Channel Pipette for 20-24 hours
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A LEVO CLA PEN AXO AMP SPX SXT MERO FUR TET CHL AUG2
4 16 1 2 4 1 2/38 2 8 4 4 16/8 A/S2 Ampicillin / Sulbactam 2:1 ratio
AMP Ampicillin
AUG2 Amoxicillin / Clavulanic Acid 2:1 ratio
B LEVO CLA PEN AXO AMP SPX SXT MERO FUR TET CHL AUG2 AXO Ceftriaxone
2 8 0.5 1 2 0.5 1/19 1 4 2 2 8/4 CHL Chloramphenicol
CLA Clarithromycin
SXT Trimethroprim / Sulfamethoxazole
C LEVO CLA PEN AXO AMP SPX SXT MERO FUR TET CHL AUG2
1 4 0.25 0.5 1 0.25 0.5/9.5 0.5 2 1 1 4/2 ERY Erythromycin
FAC Cefaclor
FEP Cefepime
D LEVO CLA PEN AXO AMP SPX SXT MERO FUR TET CHL AUG2 FIX Cefixime
0.5 2 0.12 0.25 0.5 0.12 0.25/4.75 0.25 1 0.5 0.5 2/1
FUR Cefuroxime
IMI Impenem
E LEVO CLA PEN AXO AMP SPX SXT MERO FUR TET ERY ERY LEVO Levofloxacin
0.25 1 0.06 0.12 0.25 0.06 0.12/2.38 0.12 0.5 0.25 0.25 0.5 MERO Meropenem
PEN Penicillin
SPX Sparfloxacin
LEVO CLA PEN AXO AMP SPX SXT MERO FIX FIX FIX FIX
F 0.12 0.5 0.03 0.06 0.12 0.03 0.06/1.19 0.06 0.12 0.25 0.5 1 TET Tetracycline
POS Positive control
G LEVO CLA PEN AXO FEP FEP FEP FEP FEP A/S2 A/S2 POS
0.06 0.25 0.015 0.03 0.12 0.25 0.5 1 2 1/0.5 2/1
LEVO CLA FAC FAC FAC IMI IMI IMI IMI POS POS POS
H 0.03 0.12 4 8 16 0.5 1 2 4
19
Human
Intended Use
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 10 μl or 30 μl* of the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
suspension into MHB Multi-Channel Pipette for 18-24 hours Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A CHL CHL CHL CHL ERY ERY ERY ERY ERY CLI CLI CLI
2 4 8 16 0.25 0.5 1 2 4 0.5 1 2 CHL Chloramphenicol
DAP Daptomycin
GEN Gentamicin
B DAP DAP DAP DAP OXA+ OXA+ OXA+ OXA+ OXA+ STR DT1 DT2 LZD Linezolid
0.5 1 2 4 0.25 0.5 1 2 4 1000 RIF Rifampin
SXT Trimethoprim / Sulfamethoxazole
SYN Quinupristin / Dalfopristin
C GEN GEN GEN GEN AMP AMP AMP AMP AMP AMP AMP FOXS
2 4 8 16 0.12 0.25 0.5 1 2 4 8 6 TET Tetracycline
ERY Erythromycin
OXA+ Oxacillin + 2% NaCl
D LZD LZD LZD LZD PEN PEN PEN PEN PEN PEN PEN PEN AMP Ampicillin
1 2 4 8 0.06 0.12 0.25 0.5 1 2 4 8
PEN Penicillin
VAN Vancomycin
E RIF RIF RIF RIF VAN VAN VAN VAN VAN VAN VAN VAN LEVO Levofloxacin
0.5 1 2 4 0.25 0.5 1 2 4 8 16 32 TGC Tigecycline
MXF Moxifloxacin
CLI Clindamycin
SXT SXT SXT SXT LEVO LEVO LEVO LEVO LEVO CIP CIP POS
F 0.5/9.5 1/19 2/38 4/76 0.25 0.5 1 2 4 1 2 STR Streptomycin
CIP Ciprofloxacin
NIT Nitrofurantoin
G SYN SYN SYN SYN TGC TGC TGC TGC TGC NIT NIT POS DT1 D Test 1
0.5 1 2 4 0.03 0.06 0.12 0.25 0.5 32 64
DT2 D Test 2
FOXS Cefoxitin screen
TET TET TET TET MXF MXF MXF MXF MXF GEN NEG POS NEG Negative control
H 2 4 8 16 0.25 0.5 1 2 4 500 POS Positive control
*For aid in detection of resistance mechanisms for Gram positive organisms. †Not available in Europe.
20
Human
Intended Use
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 10 μl or 30 μl* of the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
suspension into MHB Multi-Channel Pipette for 18-24 hours Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A CPT CPT CPT CPT CPT CPT AMP AMP AMP AMP AMP AMP
0.12 0.25 0.5 1 2 4 0.25 0.5 1 2 4 8 CPT Ceftaroline
CHL Chloramphenicol
CLI Clindamycin
B CHL CHL CHL CHL AXO AXO AXO AXO DAP DAP DAP DAP LZD Linezolid
2 4 8 16 8 16 32 64 0.5 1 2 4 PEN Penicillin
MXF Moxifloxacin
RIF Rifampin
C CLI CLI CLI GEN GEN LEVO LEVO LEVO LEVO LEVO DT1 DT2
0.5 1 2 4 8 0.25 0.5 1 2 4 TET Tetracycline
TGC Tigecycline
GEN Gentamicin
D LZD LZD LZD LZD VAN VAN VAN VAN VAN VAN VAN FOXS ERY Erythromycin
1 2 4 8 0.25 0.5 1 2 4 8 16 6
AXO Cetriaxone
VAN Vancomycin
E PEN PEN PEN PEN PEN PEN PEN TLA TLA TLA TLA TLA LEVO Levofloxacin
0.12 0.25 0.5 1 2 4 8 0.015 0.03 0.06 0.12 0.25 OXA+ Oxacillin + 2% NaCl
AMP Ampicillin
TLA Telavancin w/ Tween mimic
MXF MXF MXF MXF MXF OXA+ OXA+ OXA+ OXA+ SXT SXT POS
F 0.25 0.5 1 2 4 0.25 0.5 1 2 2/38 4/76 NIT Nitrofurantoin
CIP Ciprofloxacin
DAP Daptomycin
G RIF RIF TGC TGC TGC TGC TGC NIT NIT GEN STR POS SXT Trimethoprim / Sulfamethoxazole
1 2 0.03 0.06 0.12 0.25 0.5 32 64 500 1000
DT1 D Test 1
DT2 D Test 2
TET TET TET ERY ERY ERY ERY CIP CIP CIP NEG POS STR Streptomycin
H 2 4 8 0.5 1 2 4 1 2 4 FOXS Cefoxitin screen
NEG Negative control
POS Positive control
*For aid in detection of resistance mechanisms for Gram positive organisms. Not available in Europe.
†
21
Human
Intended Use
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 10 μl or 30 μl* of the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
suspension into MHB Multi-Channel Pipette for 18-24 hours Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A CPT SXT LZD TET TEI ERY TLA TOB GEN VAN RIF MUP
0.5 1/19 2 0.5 1 0.25 0.03 0.25 0.25 0.5 0.03 0.5 FOX Cefoxitin
FOXS Cefoxitin screen
CPT Ceftaroline
B CPT SXT LZD TET TEI ERY TLA TOB GEN VAN RIF MUP CLI Clindamycin
1 2/38 4 1 2 0.5 0.06 0.5 0.5 1 0.06 1 DT1 D Test 1
DT2 D Test 2
DAP Daptomycin
C CPT SXT LZD TET TEI ERY TLA TOB GEN VAN RIF MUP
2 4/76 8 2 4 1 0.12 1 1 2 0.12 2 ERY Erythromycin
FUS Fusidate
GEN Gentamicin
D CPT SXT LZD TET TEI ERY TLA TOB GEN VAN RIF MUP LEVO Levofloxacin
4 8/152 16 4 8 2 0.25 2 2 4 0.25 4
LZD Linexolid
MXF Moxifloxacin
E FUS DAP CLI LEVO TEI ERY TLA TOB GEN VAN RIF MUP MUP Mupirocin
0.5 0.5 0.12 0.5 16 4 0.5 4 4 8 0.5 8 NOR Norfloxacin
RIF Rifampin
TEI Teicoplanin
FUS DAP CLI LEVO NOR DT1 TLA TOB GEN VAN RIF MUP
F 1 1 0.25 1 4 1 8 8 16 1 256 TLA Telavancin
TET Tetracycline
TOB Tobramycin
G FUS DAP CLI LEVO NOR DT2 MXF MXF MXF MXF POS NEG SXT Trimethoprim / Sulfanethoxazole
2 2 0.5 2 8 0.25 0.5 1 2
VAN Vancomycin
NEG Negative control
FUS DAP CLI LEVO NOR FOX FOX FOX FOX FOXS POS POS POS Positive control
H 4 4 1 4 16 1 2 4 8 6
*For aid in detection of resistance mechanisms for Gram positive organisms. †Not available in Europe.
22
Human
Intended Use
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 10 μl or 30 μl* of the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
suspension into MHB Multi-Channel Pipette for 18-24 hours Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A ORI ORI ORI ORI ORI ORI ORI ORI ORI ORI ORI ORI
0.002 0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 FOXS Cefoxitin screen
CPT Chloramphenicol
CLI Clindamycin
B TLA TLA TLA TLA TLA TLA TLA TLA TLA TLA TLA TLA DT1 D Test 1
0.001 0.002 0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 DT2 D Test 2
DAL Dalbavancin
ERY Erythromycin
C CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT FOXS
0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 6 LZD Linezolid
ORI Oritavancin
OXA+ Oxacillin + 2% NaCl
D VAN VAN VAN VAN VAN VAN VAN VAN VAN VAN DT1 DT2 TZD Tedizolid
0.25 0.5 1 2 4 8 16 32 64 128
TLA Telavancin
VAN Vancomycin
E DAL DAL DAL DAL DAL DAL DAL DAL DAL CLI CLI CLI NEG Negative control
0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 0.5 1 2 POS Positive control
TZD TZD TZD TZD TZD TZD TZD TZD ERY ERY ERY ERY
F 0.03 0.06 0.12 0.25 0.5 1 2 4 0.5 1 2 4
*For aid in detection of resistance mechanisms for Gram positive organisms. †Not available in Europe.
23
Human
Intended Use
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A POS VOR VOR VOR VOR VOR VOR VOR VOR VOR VOR IZ
0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 2 FC 5-Flucytosine
FZ Fluconazole
CAS Caspofungin
B FC FC FC FC FC FC FC FC FC FC IZ IZ VOR Voriconazole
0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 0.03 1 IZ Itraconazole
POS Positive control
C FZ FZ FZ FZ FZ FZ FZ FZ FZ FZ IZ IZ
0.25 0.5 1 2 4 8 16 32 64 32 0.06 0.5
D CAS CAS CAS CAS CAS CAS CAS CAS CAS CAS IZ IZ
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 0.12 0.25
E POS VOR VOR VOR VOR VOR VOR VOR VOR VOR VOR IZ
0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 2
FC FC FC FC FC FC FC FC FC FC IZ IZ
F 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 0.03 1
G FZ FZ FZ FZ FZ FZ FZ FZ FZ FC IZ IZ
0.25 0.5 1 2 4 8 16 32 64 32 0.06 0.5
CAS CAS CAS CAS CAS CAS CAS CAS CAS CAS IZ IZ
H 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 0.12 0.25
24
Human
Intended Use
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A POS
FC 5-Flucytosine
FZ Fluconazole
CAS Caspofungin
B VOR VOR VOR VOR VOR VOR VOR VOR VOR VOR VOR VOR VOR Voriconazole
0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 IZ Itraconazole
MF Micafungin
D FZ FZ FZ FZ FZ FZ FZ FZ FZ FZ FZ FZ
0.12 0.25 0.5 1 2 4 8 16 32 64 128 256
E CAS CAS CAS CAS CAS CAS CAS CAS CAS CAS CAS CAS
0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16
IZ IZ IZ IZ IZ IZ IZ IZ IZ IZ IZ IZ
F 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16
G MF MF MF MF MF MF MF MF MF MF MF MF
0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16
25
Human
Intended Use
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A POS AND AND AND AND AND AND AND AND AND AND AB
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 0.12 AND Anidulafungin
AB Amphotericin B
MF Micafungin
B MF MF MF MF MF MF MF MF MF MF MF AB CAS Caspofungin
0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 0.25 FC 5-Flucytosine
PZ Posaconazole
VOR Voriconazole
C CAS CAS CAS CAS CAS CAS CAS CAS CAS CAS CAS AB
0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 0.5 IZ Itraconazole
FZ Fluconazole
POS Positive control
D FC FC FC FC FC FC FC FC FC FC FC AB
0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 1
E PZ PZ PZ PZ PZ PZ PZ PZ PZ PZ PZ AB
0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 2
VOR VOR VOR VOR VOR VOR VOR VOR VOR VOR VOR AB
F 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 4
G IZ IZ IZ IZ IZ IZ IZ IZ IZ IZ IZ AB
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 8
FZ FZ FZ FZ FZ FZ FZ FZ FZ FZ FZ FZ
H 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256
26
Human
Intended Use
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A POS AND AND AND AND AND AND AND AND AND AND AB
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 0.12 AND Anidulafungin
AB Amphotericin B
MF Micafungin
B MF MF MF MF MF MF MF MF MF MF MF AB CAS Caspofungin
0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 0.25 FC 5-Flucytosine
PZ Posaconazole
VOR Voriconazole
C CAS CAS CAS CAS CAS CAS CAS CAS CAS CAS CAS AB
0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 0.5 IZ Itraconazole
FZ Fluconazole
POS Positive control
D FC FC FC FC FC FC FC FC FC FC FC AB
0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 1
E PZ PZ PZ PZ PZ PZ PZ PZ PZ PZ PZ AB
0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 2
VOR VOR VOR VOR VOR VOR VOR VOR VOR VOR VOR AB
F 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 4
G IZ IZ IZ IZ IZ IZ IZ IZ IZ IZ IZ AB
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 8
FZ FZ FZ FZ FZ FZ FZ FZ FZ FZ FZ FZ
H 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256
27
Human
Determiniation of MICs to first and second-line anti-tuberculosis drugs for Mycobacterium tuberculosis isolates
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A OFL MXF RIF AMI STR RFB PAS ETH CYC INH KAN EMB
32 8 16 16 32 16 64 40 256 4 40 OFL Ofloxacin
32
MXF Moxifloxacin
RIF Rifampin
B OFL MXF RIF AMI STR RFB PAS ETH CYC INH KAN EMB AMI Amikacin
16 4 8 8 16 8 32 20 128 2 20 16 STR Streptomycin
RFB Rifabutin
PAS Para-aminosalicylic acid
C OFL MXF RIF AMI STR RFB PAS ETH CYC INH KAN EMB
8 2 4 4 8 4 16 10 64 1 10 8 ETH Ethionamide
CYC Cycloserine
INH Isoniazid
D OFL MXF RIF AMI STR RFB PAS ETH CYC INH KAN EMB KAN Kanamycin
4 1 2 2 4 2 8 5 32 0.5 5 4
EMB Ethambutol
POS Positive control
E OFL MXF RIF AMI STR RFB PAS ETH CYC INH KAN EMB
2 0.5 1 1 2 1 4 2.5 16 0.25 2.5 2
OFL MXF RIF AMI STR RFB PAS ETH CYC INH KAN EMB
F 1 0.25 0.5 0.5 1 0.5 2 1.2 8 0.12 1.2 1
G OFL MXF RIF AMI STR RFB PAS ETH CYC INH KAN EMB
0.5 0.12 0.25 0.25 0.5 0.25 1 0.6 4 0.06 0.6 0.5
OFL MXF RIF AMI STR RFB PAS ETH CYC INH POS POS
H 0.25 0.06 0.12 0.12 0.25 0.12 0.5 0.3 2 0.03
28
Human
Determiniation of MICs to first and second-line anti-tuberculosis drugs for Mycobacterium tuberculosis isolates
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A OFL MXF RIF AMI STR RFB PAS ETH CYC INH KAN EMB
32 8 16 16 32 16 64 40 256 4 40 OFL Ofloxacin
32
MXF Moxifloxacin
RIF Rifampin
B OFL MXF RIF AMI STR RFB PAS ETH CYC INH KAN EMB AMI Amikacin
16 4 8 8 16 8 32 20 128 2 20 16 STR Streptomycin
RFB Rifabutin
PAS Para-aminosalicylic acid
C OFL MXF RIF AMI STR RFB PAS ETH CYC INH KAN EMB
8 2 4 4 8 4 16 10 64 1 10 8 ETH Ethionamide
CYC Cycloserine
INH Isoniazid
D OFL MXF RIF AMI STR RFB PAS ETH CYC INH KAN EMB KAN Kanamycin
4 1 2 2 4 2 8 5 32 0.5 5 4
EMB Ethambutol
POS Positive control
E OFL MXF RIF AMI STR RFB PAS ETH CYC INH KAN EMB
2 0.5 1 1 2 1 4 2.5 16 0.25 2.5 2
OFL MXF RIF AMI STR RFB PAS ETH CYC INH KAN EMB
F 1 0.25 0.5 0.5 1 0.5 2 1.2 8 0.12 1.2 1
G OFL MXF RIF AMI STR RFB PAS ETH CYC INH KAN EMB
0.5 0.12 0.25 0.25 0.5 0.25 1 0.6 4 0.06 0.6 0.5
OFL MXF RIF AMI STR RFB PAS ETH CYC INH POS POS
H 0.25 0.06 0.12 0.12 0.25 0.12 0.5 0.3 2 0.03
29
Human
Susceptibility testing of rapidly growing mycobacteria, Nocardia spp., and other aerobic actinomycetes
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A SXT SXT SXT SXT SXT SXT LZD LZD LZD LZD LZD LZD
0.25/4.75 0.5/9.5 1/19 2/38 4/76 8/152 1 2 4 8 16 32 SXT Trimethoprim / Sulfamethoxazole
CIP Ciprofloxacin
MXF Moxifloxacin
B CIP CIP CIP CIP CIP CIP IMI IMI IMI IMI IMI IMI FOX Cefoxitin
0.12 0.25 0.5 1 2 4 2 4 8 16 32 64 AMI Amikacin
DOX Doxycycline
TGC Tigecycline
C MXF MXF MXF MXF MXF MXF FEP FEP FEP FEP FEP FEP
0.25 0.5 1 2 4 8 1 2 4 8 16 32 CLA Clarithromycin
LZD Linezolid
IMI Imipenem
D FOX FOX FOX FOX FOX FOX AUG2 AUG2 AUG2 AUG2 AUG2 AUG2 FEP Cefepime
4 8 16 32 64 128 2/1 4/2 8/4 16/8 32/16 64/32
AUG2 Amoxicillin / Clavulanic acid 2:1 ratio
AXO Ceftriaxone
E AMI AMI AMI AMI AMI AMI AMI AXO AXO AXO AXO AXO MIN Minocycline
1 2 4 8 16 32 64 4 8 16 32 64 TOB Tobramycin
POS Positive control
DOX DOX DOX DOX DOX DOX DOX DOX MIN MIN MIN MIN
F 0.12 0.25 0.5 1 2 4 8 16 1 2 4 8
G TGC TGC TGC TGC TGC TGC TGC TGC TGC TOB TOB TOB
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 1 2 4
CLA CLA CLA CLA CLA CLA CLA CLA CLA TOB TOB POS
H 0.06 0.12 0.25 0.5 1 2 4 8 16 8 16
*For Nocardia spp. and other aerobic actinomycetes, incubate at 35°C in a non-CO2 incubator for 2-3 days.
30
Human
Susceptibility testing of rapidly growing mycobacteria, Nocardia spp., and other aerobic actinomycetes
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A SXT SXT SXT SXT SXT SXT LZD LZD LZD LZD LZD LZD
0.25/4.75 0.5/9.5 1/19 2/38 4/76 8/152 1 2 4 8 16 32 SXT Trimethoprim / Sulfamethoxazole
CIP Ciprofloxacin
MXF Moxifloxacin
B CIP CIP CIP CIP CIP CIP IMI IMI IMI IMI IMI IMI FOX Cefoxitin
0.12 0.25 0.5 1 2 4 2 4 8 16 32 64 AMI Amikacin
DOX Doxycycline
TGC Tigecycline
C MXF MXF MXF MXF MXF MXF FEP FEP FEP FEP FEP FEP
0.25 0.5 1 2 4 8 1 2 4 8 16 32 CLA Clarithromycin
LZD Linezolid
IMI Imipenem
D FOX FOX FOX FOX FOX FOX AUG2 AUG2 AUG2 AUG2 AUG2 AUG2 FEP Cefepime
4 8 16 32 64 128 2/1 4/2 8/4 16/8 32/16 64/32
AUG2 Amoxicillin / Clavulanic acid 2:1 ratio
AXO Ceftriaxone
E AMI AMI AMI AMI AMI AMI AMI AXO AXO AXO AXO AXO MIN Minocycline
1 2 4 8 16 32 64 4 8 16 32 64 TOB Tobramycin
POS Positive control
DOX DOX DOX DOX DOX DOX DOX DOX MIN MIN MIN MIN
F 0.12 0.25 0.5 1 2 4 8 16 1 2 4 8
G TGC TGC TGC TGC TGC TGC TGC TGC TGC TOB TOB TOB
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 1 2 4
CLA CLA CLA CLA CLA CLA CLA CLA CLA TOB TOB POS
H 0.06 0.12 0.25 0.5 1 2 4 8 16 8 16
*For Nocardia spp. and other aerobic actinomycetes, incubate at 35°C in a non-CO 2 incubator for 2-3 days.
31
Human
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A CLA CLA CLA CLA CLA CLA CLA CLA CIP STR DOX ETH
0.06 0.12 0.25 0.5 1 2 4 8 16 64 16 20 CLA Clarithromycin
RFB Rifabutin
EMB Ethambutol
B CLA CLA CLA MXF RIF SXT AMI LZD CIP STR DOX ETH INH Isoniazid
16 32 64 8 8 8/152 64 64 8 32 8 10 MXF Moxifloxacin
RIF Rifampin
SXT Trimethoprim / Sulfamethoxazole
C RFB EMB INH MXF RIF SXT AMI LZD CIP STR DOX ETH
8 16 8 4 4 4/76 32 32 4 16 4 5 AMI Amikacin
LZD Linezolid
CIP Ciprofloxacin
D RFB EMB INH MXF RIF SXT AMI LZD CIP STR DOX ETH STR Streptomycin
4 8 4 2 2 2/38 16 16 2 8 2 2.5
DOX Doxycycline
ETH Ethionamide
E RFB EMB INH MXF RIF SXT AMI LZD CIP STR DOX ETH POS Positive control
2 4 2 1 1 1/19 8 8 1 4 1 1.2
RFB EMB INH MXF RIF SXT AMI LZD CIP STR DOX ETH
F 1 2 1 0.5 0.5 0.5/9.5 4 4 0.5 2 0.5 0.6
G RFB EMB INH MXF RIF SXT AMI LZD CIP STR DOX ETH
0.5 1 0.5 0.25 0.25 0.25/4.75 2 2 0.25 1 0.25 0.3
RFB EMB INH MXF RIF SXT AMI LZD CIP STR DOX POS
H 0.25 0.5 0.25 0.12 0.12 0.12/2.38 1 1 0.12 0.5 0.12
32
Human
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A CLA CLA CLA CLA CLA CLA CLA CLA CIP STR DOX ETH
0.06 0.12 0.25 0.5 1 2 4 8 16 64 16 20 CLA Clarithromycin
RFB Rifabutin
EMB Ethambutol
B CLA CLA CLA MXF RIF SXT AMI LZD CIP STR DOX ETH INH Isoniazid
16 32 64 8 8 8/152 64 64 8 32 8 10 MXF Moxifloxacin
RIF Rifampin
SXT Trimethoprim / Sulfamethoxazole
C RFB EMB INH MXF RIF SXT AMI LZD CIP STR DOX ETH
8 16 8 4 4 4/76 32 32 4 16 4 5 AMI Amikacin
LZD Linezolid
CIP Ciprofloxacin
D RFB EMB INH MXF RIF SXT AMI LZD CIP STR DOX ETH STR Streptomycin
4 8 4 2 2 2/38 16 16 2 8 2 2.5
DOX Doxycycline
ETH Ethionamide
E RFB EMB INH MXF RIF SXT AMI LZD CIP STR DOX ETH POS Positive control
2 4 2 1 1 1/19 8 8 1 4 1 1.2
RFB EMB INH MXF RIF SXT AMI LZD CIP STR DOX ETH
F 1 2 1 0.5 0.5 0.5/9.5 4 4 0.5 2 0.5 0.6
G RFB EMB INH MXF RIF SXT AMI LZD CIP STR DOX ETH
0.5 1 0.5 0.25 0.25 0.25/4.75 2 2 0.25 1 0.25 0.3
RFB EMB INH MXF RIF SXT AMI LZD CIP STR DOX POS
H 0.25 0.5 0.25 0.12 0.12 0.12/2.38 1 1 0.12 0.5 0.12
33
VETERINARY
Avian Mastitis
Bovine/Porcine Urine
Companion Topical
Equine
34
Veterinary
Intended Use
Antimicrobial susceptibility plate for testing non-fastidious Gram positive and Gram negative isolates of veterinary origin
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 1 μl*, 10 μl, or 30 μl** the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
of suspension into MHB Multi-Channel Pipette for 18-24 hours*** Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A ENRO ENRO ENRO ENRO ENRO SPE SDM FFN PEN STR NOV CLI
2 1 0.5 0.25 0.12 64 256 8 8 1024 4 4 ENRO Enrofloxacin
GEN Gentamicin
XNL Ceftiofur
B GEN GEN GEN GEN GEN SPE SDM FFN PEN STR NOV CLI NEO Neomycin
8 4 2 1 0.5 32 128 4 4 512 2 2 ERY Erythromycin
OXY Oxytetracycline
TET Tetracycline
C XNL XNL XNL XNL XNL SPE SDM FFN PEN STR NOV CLI
4 2 1 0.5 0.25 16 64 2 2 256 1 1 AMOX Amoxicillin
SPE Spectinomycin
SDM Sulphadimethoxine
D NEO NEO NEO NEO NEO SPE SDM FFN PEN STR NOV CLI SXT Trimethoprim / Sulfamethoxazole
32 16 8 4 2 8 32 1 1 128 0.5 0.5
FFN Florfenicol
STZ Sulphathiazole
E ERY ERY ERY ERY ERY ERY SXT STZ PEN STR TYLT NEG PEN Penicillin
4 2 1 0.5 0.25 0.12 2/38 256 0.5 64 20 STR Streptomycin
NOV Novobiocin
TYLT Tylosin tartrate
OXY OXY OXY OXY OXY OXY SXT STZ PEN STR TYLT POS
F 8 4 2 1 0.5 0.25 1/19 128 0.25 32 10 CLI Clindamycin
NEG Negative control
POS Positive control
G TET TET TET TET TET TET SXT STZ PEN STR TYLT POS
8 4 2 1 0.5 0.25 0.5/9.5 64 0.12 16 5
AMOX AMOX AMOX AMOX AMOX AMOX AMOX STZ PEN STR TYLT POS
H 16 8 4 2 1 0.5 0.25 32 0.06 8 2.5
*For Proteus spp. **Ensure detection of hetero-resistant isolates among Staphylococcus and Enterococcus spp.
***Incubate for 24 hours to ensure detection of oxacillin-resistant Staphylococcus and vancomycin-resistant Enterococcus spp. †Not available in Europe.
35
Veterinary
Intended Use
Antimicrobial susceptibility plate for testing non-fastidious Gram positive and Gram negative isolates of veterinary origin
(For Streptococcus pneumoniae and Actinobacillus pleuropneumoniae isolates, contact your local Thermo Fisher Scientific Microbiology respresentative for
protocol specifications)
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 1 μl*, 10 μl, or 30 μl** the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
of suspension into MHB Multi-Channel Pipette for 18-24 hours*** Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A AMI AMI AMI AMI AMP AMP AMP AMP AMP AMP AMP AMP
4 8 16 32 0.25 0.5 1 2 4 8 16 32 AMI Amikacin
AZI Azithromycin
XNL Ceftiofur
B AZI AZI AZI AZI AZI FAZ FAZ FAZ SXT SXT SXT SXT CHL Chloramphenicol
0.25 0.5 1 2 4 4 8 16 0.5/9.5 1/19 2/38 4/76 ENRO Enrofloxacin
OXA+ Oxacillin + 2% NaCl
PEN Penicillin
C XNL XNL XNL XNL XNL TAZ TAZ TAZ TAZ TAZ TAZ TAZ
0.25 0.5 1 2 4 1 2 4 8 16 32 64 TIC Ticarcillin
AMP Ampicillin
CLA Clarithromycin
D CHL CHL CHL CHL CLA CLA CLA CLA DOX DOX DOX DOX GEN Gentamicin
4 8 16 32 1 2 4 8 2 4 8 16
TIM2 Ticarcillin / Clavulanic acid constant 2
FAZ Cefazolin
E ENRO ENRO ENRO ENRO GEN GEN GEN GEN IMI IMI IMI IMI TAZ Ceftazidime
0.25 0.25 1 2 1 2 4 8 1 2 4 8 ERY Erythromycin
SXT Trimethoprim / Sulfamethoxazole
DOX Doxycycline
OXA+ OXA+ OXA+ OXA+ OXA+ ERY ERY ERY ERY ERY ERY POS
F 0.25 0.5 1 2 4 0.25 0.5 1 2 4 8 IMI Imipenem
RIF Rifampin
TET Tetracycline
G PEN PEN PEN PEN PEN PEN PEN PEN RIF RIF RIF POS POS Positive Control
0.06 0.12 0.25 0.5 1 2 4 8 1 2 4
TIC TIC TIC TIC TIM2 TIM2 TIM2 TIM2 TET TET TET POS
H 8 16 32 64 8/2 16/2 32/2 64/2 2 4 8
*For Proteus spp. **Ensure detection of hetero-resistant isolates among Staphylococcus and Enterococcus spp.
***Incubate for 24 hours to ensure detection of oxacillin-resistant Staphylococcus and vancomycin-resistant Enterococcus spp. †Not available in Europe.
36
Veterinary
Intended Use
Antimicrobial susceptibility plate for testing non-fastidious Gram positive and Gram negative isolates of veterinary origin
(For Mannheimia hemolytica, Pasteurella multocida, Bordetella bronchiseptica, Streptococcus pneumoniae, Histophilus somni, and Actinobacillus pleuropneumoniae
isolates, contact your local Thermo Fisher Microbiology respresentative for protocol specifications)
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 1 μl*, 10 μl, or 30 μl** the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
of suspension into MHB Multi-Channel Pipette for 18-24 hours*** Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A XNL TIA CTET OXY PEN AMP DANO SXT TYLT TUL CLI SDM
8 32 8 8 8 16 1 2/38 4 4 16 256 XNL Ceftiofur
TIA Tiamulin
CTET Chlortetracycline
B XNL TIA CTET OXY PEN AMP DANO SPE TYLT TUL CLI ENRO GEN Gentamicin
4 16 4 4 4 8 0.5 64 2 2 8 2 FFN Florfenicol
OXY Oxytetracycline
PEN Penicillin
C XNL TIA CTET OXY PEN AMP DANO SPE TYLT TUL CLI ENRO
2 8 2 2 2 4 0.25 32 1 1 4 1 AMP Ampicillin
DANO Danofloxacin
SDM Sulphadimethoxine
D XNL TIA CTET OXY PEN AMP DANO SPE TYLT TIL CLI ENRO NEO Neomycin
1 4 1 1 1 2 0.12 16 0.5 64 2 0.5
SXT Trimethoprim / Sulfamethoxazole
SPE Spectinomycin
E XNL TIA CTET OXY PEN AMP NEO SPE TUL TIL CLI ENRO TYLT Tylosin tartrate
0.5 2 0.5 0.5 0.5 1 32 8 64 32 1 0.25 TUL Tulathromycin
TIL Tilmicosin
CLI Clindamycin
XNL TIA TIA GEN PEN AMP NEO TYLT TUL TIL CLI ENRO
F 0.25 1 0.5 16 0.25 0.5 16 32 32 16 0.5 0.12 ENRO Enrofloxacin
POS Positive control
G GEN GEN GEN GEN PEN AMP NEO TYLT TUL TIL CLI POS
8 4 2 1 0.12 0.25 8 16 16 8 0.25
FFN FFN FFN FFN FFN FFN NEO TYLT TUL TIL POS POS
H 8 4 2 1 0.5 0.25 4 8 8 4
*For Proteus spp. **Ensure detection of hetero-resistant isolates among Staphylococcus and Enterococcus spp.
***Incubate for 24 hours to ensure detection of oxacillin-resistant Staphylococcus and vancomycin-resistant Enterococcus spp. †Not available in Europe.
37
The latest antimicrobials
to combat bovine
respiratory disease
As the first standard format AST solution to include gamithromycin and tildipirosin for bovine/porcine applications, the
Sensititre Bovine BOPO7F Plate delivers host animal-specific results on a single plate, enabling faster, more effective
therapy intervention and improved animal outcomes. The Sensititre Bovine BOPO7F Plate features:
*Contact Thermo Fisher Scientific Microbiology Technical Support to add new breakpoint updates to
your Thermo Scientific™ Sensititre™ SWIN ™ Software.
Not all products are available for sale in all territories. Please inquire.
38
Veterinary
Intended Use
Antimicrobial susceptibility plate for testing non-fastidious Gram positive and Gram negative isolates of veterinary origin
(For Mannheimia hemolytica, Pasteurella multocida, Bordetella bronchiseptica, Streptococcus pneumoniae, Histophilus somni, and Actinobacillus pleuropneumoniae
isolates, contact your local Thermo Fisher Microbiology respresentative for protocol specifications)
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 1 μl*, 10 μl, or 30 μl** the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
of suspension into MHB Multi-Channel Pipette for 18-24 hours*** Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A PEN PEN PEN PEN PEN PEN PEN TET TET TET TET TET
0.12 0.25 0.5 1 2 4 8 0.5 1 2 4 8 GAM Gamithromycin
AMP Ampicillin
XNL Ceftiofur
B AMP AMP AMP AMP AMP AMP AMP GEN GEN GEN GEN GEN CLI Clindamycin
0.25 0.5 1 2 4 8 16 1 2 4 8 16 DANO Danofloxacin
ENRO Enrofloxacin
FFN Florfenicol
C TIA TIA TIA TIA TIA TIA TIA TIP TIP TIP TIP TIP
0.5 1 2 4 8 16 32 1 2 4 8 16 GEN Gentamicin
NEO Neomycin
PEN Penicillin
D TYLT TYLT TYLT TYLT TYLT TYLT TYLT TIL TIL TIL TIL NEO SPE Spectinomycin
0.5 1 2 4 8 16 32 2 4 8 16 4
SDM Sulphadimethoxine
TET Tetracycline
E NEO NEO NEO TUL TUL TUL TUL ENRO ENRO ENRO ENRO ENRO TIA Tiamulin
8 16 32 8 16 32 64 0.12 0.25 0.5 1 2 TIP Tildipirosin
TIL Tilmicosin
SXT Trimethoprim / Sulfamethoxazole
CLI CLI CLI CLI CLI CLI CLI DANO DANO DANO DANO POS
F 0.25 0.5 1 2 4 8 16 0.12 0.25 0.5 1 TUL Tulathromycin
TYLT Tylosin tartrate
POS Positive control
G XNL XNL XNL XNL XNL XNL GAM GAM GAM GAM SDM POS
0.25 0.5 1 2 4 8 1 2 4 8 256
FFN FFN FFN FFN FFN FFN SPE SPE SPE SPE SXT POS
H 0.25 0.5 1 2 4 8 8 16 32 64 2/38
*For Proteus spp. **Ensure detection of hetero-resistant isolates among Staphylococcus and Enterococcus spp.
***Incubate for 24 hours to ensure detection of oxacillin-resistant Staphylococcus and vancomycin-resistant Enterococcus spp. †Not available in Europe.
39
More choice.
More performance.
40
Veterinary
Antimicrobial susceptibility plate for testing non-fastidious Gram positive isolates of veterinary origin
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 10 μl or 30 μl* of the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
suspension into MHB Multi-Channel Pipette for 18-24 hours** Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A AMP AMP AMP AMP AMP AMP AUG2 AUG2 AUG2 AUG2 AUG2 AUG2
0.25 0.5 1 2 4 8 0.25/0.12 0.5/0.25 1/0.5 2/1 4/2 8/4 AMI Amikacin
AUG2 Amoxicillin / Clavulanic acid 2:1 ratio
AMP Ampicillin
B CEP CEP FAZ FAZ SXT SXT MIN MIN MIN MAR MAR MAR FAZ Cefazolin
2 4 2 4 2/38 4/76 0.5 1 2 1 2 4 FOV Cefovecin
POD Cefopodoxime
CEP Cephalothin
C ERY ERY ERY ERY ERY CHL CHL CHL PRA PRA PRA PRA
0.25 0.5 1 2 4 8 16 32 0.25 0.5 1 2 CHL Chloramphenicol
CLI Clindamycin
DOX Doxycycline
D PEN PEN PEN PEN PEN PEN PEN PEN CLI CLI CLI CLI ENRO Enrofloxacin
0.06 0.12 0.25 0.5 1 2 4 8 0.5 1 2 4
ERY Erythromycin
GEN Gentamicin
E AMI AMI NIT NIT NIT IMI IMI IMI DOX DOX DOX NEG IMI Impenem
16 32 16 32 64 1 2 4 0.12 0.25 0.5 MAR Marbofloxacin
MIN Minocycline
NIT Nitrofurantoin
ENRO ENRO ENRO ENRO ENRO TET TET TET GEN GEN GEN POS
F 0.25 0.5 1 2 4 0.25 0.5 1 4 8 16 OXA+ Oxacillin + 2% NaCl
PEN Penicillin
PRA Pradofloxacin
G POD POD POD FOV FOV FOV FOV FOV FOV FOV FOV POS RIF Rifampin
2 4 8 0.06 0.12 0.25 0.5 1 2 4 8
TET Tetracycline
SXT Trimethoprim / Sulfamethoxazole
VAN VAN VAN VAN VAN OXA+ OXA+ OXA+ OXA+ RIF RIF POS VAN Vancomycin
H 1 2 4 8 16 0.25 0.5 1 2 1 2 NEG Negative control
POS Positive control
41
Veterinary
Antimicrobial susceptibility plate for testing non-fastidious Gram negative isolates of veterinary origin
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 1 μl* or 10 μl of the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
suspension into MHB Multi-Channel Pipette for 18-24 hours Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A AMP AMP AMP AMP AMP AMP AUG2 AUG2 AUG2 AUG2 AUG2 AUG2
0.25 0.5 1 2 4 8 0.25/0.12 0.5/0.25 1/0.5 2/1 4/2 8/4 AMI Amikacin
AUG2 Amoxicillin / Clavulanic acid 2:1 ratio
AMP Ampicillin
B POD POD POD POD PRA PRA PRA PRA SXT SXT SXT SXT FAZ Cefazolin
1 2 4 8 0.25 0.5 1 2 0.5/9.5 1/19 2/38 4/76 FOV Cefovecin
POD Cefopodoxime
TAZ Ceftazidime
C FOV FOV FOV FOV FOV FOV GEN GEN GEN GEN GEN GEN
0.25 0.5 1 2 4 8 0.25 0.5 1 2 4 8 LEX Cephalexin
CHL Chloramphenicol
DOX Doxycycline
D LEX LEX LEX LEX LEX LEX DOX DOX DOX DOX DOX DOX ENRO Enrofloxacin
0.5 1 2 4 8 16 0.25 0.5 1 2 4 8
GEN Gentamicin
IMI Impenem
E IMI IMI IMI IMI ORB ORB ORB ORB AMI AMI AMI AMI MAR Marbofloxacin
1 2 4 8 1 2 4 8 4 8 16 32 ORB Orbifloxacin
P/T4 Piperacillin / Tazobactam contant 4
PRA Pradofloxacin
FAZ FAZ FAZ FAZ FAZ FAZ MAR MAR MAR MAR MAR MAR
F 1 2 4 8 16 32 0.12 0.25 0.5 1 2 4 TET Tetracycline
SXT Trimethoprim / Sulfamethoxazole
POS Positive control
G ENRO ENRO ENRO ENRO ENRO ENRO CHL CHL CHL CHL CHL POS
0.12 0.25 0.5 1 2 4 2 4 8 16 32
P/T4 P/T4 P/T4 P/T4 TET TET TET TAZ TAZ TAZ POS POS
H 8/4 16/4 32/4 64/4 4 8 16 4 8 16
42
Veterinary
Intended Use
Antimicrobial susceptibility plate for testing non-fastidious Gram positive and Gram negative isolates of veterinary origin
(For Streptococcus pneumoniae isolates, contact your local Thermo Fisher Scientific Microbiology representative for protocol specifications)
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 1 μl*, 10 μl, or 30 μl** of the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
suspension into MHB Multi-Channel Pipette for 18-24 hours*** Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A POS POS POS PIRL TET XNL POS POS POS PIRL TET XNL
4 8 4 4 8 4 AMP Ampicillin
PEN Penicillin
ERY Erythromycin
B AMP PEN ERY PIRL TET XNL AMP PEN ERY PIRL TET XNL OXA+ Oxacillin +2% NaCl
8 8 4 2 4 2 8 8 4 2 4 2 PIRL Pirlamycin
P/N Penicillin / Novobiocin
TET Tetracycline
C AMP PEN ERY PIRL TET XNL AMP PEN ERY PIRL TET XNL
4 4 2 1 2 1 4 4 2 1 2 1 CEP Cephalothin
XNL Ceftiofur
SDM Sulphadimethoxine
D AMP PEN ERY PIRL TET XNL AMP PEN ERY PIRL TET XNL POS Positive control
2 2 1 0.5 1 0.5 2 2 1 0.5 1 0.5
E AMP PEN ERY P/N CEP SDM AMP PEN ERY P/N CEP SDM
1 1 0.5 8/16 16 256 1 1 0.5 8/16 16 256
AMP PEN ERY P/N CEP SDM AMP PEN ERY P/N CEP SDM
F 0.5 0.5 0.25 4/8 8 128 0.5 0.5 0.25 4/8 8 128
G AMP PEN OXA+ P/N CEP SDM AMP PEN OXA+ P/N CEP SDM
0.25 0.25 4 2/4 4 64 0.25 0.25 4 2/4 4 64
AMP PEN OXA+ P/N CEP SDM AMP PEN OXA+ P/N CEP SDM
H 0.12 0.12 2 1/2 2 32 0.12 0.12 2 1/2 2 32
*For Proteus spp. **Ensure detection of hetero-resistant isolates among Staphylococcus and Enterococcus spp.
***Incubate for 24 hours to ensure detection of oxacillin-resistant Staphylococcus and vancomycin-resistant Enterococcus spp. †Not available in Europe.
43
Veterinary
Intended Use
Antimicrobial susceptibility plate for testing non-fastidious Gram positive and Gram negative isolates of veterinary origin
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and Automatically read with
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
using the Nephelometer, the suspension using a non-CO2 incubator or or manually read with
Mix 1 μl*, 10 μl, or 30 μl** of the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
suspension into MHB Multi-Channel Pipette for 18-24 hours*** Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A POS POS POS AMP AUG2 ENRO POS POS POS AMP AUG2 ENRO
256 256/128 4 256 256/128 4 SXT Trimethoprim / Sulfamethoxazole
XNL Ceftiofur
TET Tetracycline
B SXT TET LEX AMP AUG2 ENRO SXT TET LEX AMP AUG2 ENRO LEX Cephalexin
8/152 128 256 128 128/64 2 8/152 128 256 128 128/64 2 AMP Ampicillin
AUG2 Amoxicillin / Clavulanic acid 2:1 ratio
SXT TET LEX AMP AUG2 ENRO SXT TET LEX AMP AUG2 ENRO ENRO Enrofloxacin
C
4/76 64 128 64 64/32 1 4/76 64 128 64 64/32 1 POS Positive control
D SXT TET LEX AMP AUG2 ENRO SXT TET LEX AMP AUG2 ENRO
2/38 32 64 32 32/16 0.5 2/38 32 64 32 32/16 0.5
E XNL TET LEX AMP AUG2 ENRO XNL TET LEX AMP AUG2 ENRO
4 16 32 16 16/8 0.25 4 16 32 16 16/8 0.25
XNL TET LEX AMP AUG2 ENRO XNL TET LEX AMP AUG2 ENRO
F 2 8 16 8 8/4 0.12 2 8 16 8 8/4 0.12
G XNL TET LEX AMP AUG2 ENRO XNL TET LEX AMP AUG2 ENRO
1 4 8 4 4/2 0.06 1 4 8 4 4/2 0.06
XNL TET LEX AMP AUG2 ENRO XNL TET LEX AMP AUG2 ENRO
H 0.5 2 4 2 2/1 0.03 0.5 2 4 2 2/1 0.03
*For Proteus spp. **Ensure detection of hetero-resistant isolates among Staphylococcus and Enterococcus spp.
***Incubate for 24 hours to ensure detection of oxacillin-resistant Staphylococcus and vancomycin-resistant Enterococcus spp. †Not available in Europe.
44
Veterinary
Perform accurate AST with this dual-isolate plate for breakpoint testing of topical compounds
Put 3-5 colonies into H20 to Inoculate plate with Seal Sensititre plate and
o
measure a 0.5 McFarland 50 μl volume per well of incubate at 34-36 C in Manually read with
using the Nephelometer, the suspension using a non-CO2 incubator or Sensititre Vizion or
Mix 10 μl of suspension the Sensititre AIM or Sensititre ARIS 2X† Sensititre Manual Viewbox
into MHB Multi-Channel Pipette for 18-24 hours
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A POS CIP CIP CIP MXF MXF POS CIP CIP CIP MXF MXF
1 2 4 0.5 1 1 2 4 0.5 1 ERY Erythromycin
OXY Oxytetracycline
GEN Gentamicin
B ERY ERY ERY ERY NEO NEO ERY ERY ERY ERY NEO NEO CHL Chloramphenicol
0.5 1 2 4 4 8 0.5 1 2 4 4 8 OFL Ofloxacin
BAC Bacitracin
DOX Doxycycline
C OXY OXY OXY OXY AMI AMI OXY OXY OXY OXY AMI AMI
0.5 1 2 4 16 32 0.5 1 2 4 16 32 CIP Ciprofloxacin
XNL Ceftiofur
TIC Ticarcillin
D GEN GEN GEN TIC TIC TIC GEN GEN GEN TIC TIC TIC TOB Tobramycin
2 4 8 16 32 64 2 4 8 16 32 64
MXF Moxifloxacin
NEO Neomycin
E CHL CHL CHL TOB TOB TOB CHL CHL CHL TOB TOB TOB AMI Amikacin
4 8 16 4 8 16 4 8 16 4 8 16 POL Polymixin B
FAZ Cefazolin
SXT Trimethoprim / Sulfamethoxazole
OFL OFL OFL OFL POL POL OFL OFL OFL OFL POL POL
F 0.12 0.25 0.5 1 5 10 0.12 0.25 0.5 1 5 10 POS Positive control
G BAC BAC XNL XNL FAZ FAZ BAC BAC XNL XNL FAZ FAZ
2 4 2 4 8 16 2 4 2 4 8 16
DOX DOX DOX DOX DOX SXT DOX DOX DOX DOX DOX SXT
H 0.12 0.25 0.5 1 2 2/38 0.12 0.25 0.5 1 2 2/38
†
Not available in Europe.
45
SURVEILLANCE
46
Surveillance
Antimicrobial susceptibility plate for testing Salmonella and Escherichia coli isolates as part of The National Antimicrobial
Resistance Monitoring System (NARMS) program in the United States
Inoculate plate with Seal Sensititre plate and Automatically read with
Put 3-5 colonies into H20 o
50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
to measure a 0.5 McFarland
the suspension using a non-CO2 incubator or or manually read with
using the Nephelometer, Mix
the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
10 μl of suspension into MHB
Multi-Channel Pipette for 18 hours Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A FOX AZI CHL AXO AXO CIP GEN NAL XNL FIS AMP STR
32 8 16 64 0.25 2 16 16 2 32 32 16 FOX Cefoxitin
AZI Azithromycin
CHL Chloramphenicol
B FOX AZI CHL AXO AUG2 CIP GEN NAL XNL FIS AMP STR TET Tetracycline
16 4 8 32 32/16 1 8 8 1 16 16 8 AXO Ceftriaxone
AUG2 Amoxicillin / Clavulanic acid 2:1 ratio
CIP Ciprofloxacin
C FOX AZI CHL AXO AUG2 CIP GEN NAL XNL SXT AMI STR
8 2 4 16 16/8 0.5 4 4 0.5 4/76 8 4 GEN Gentamicin
NAL Nalidixic Acid
XNL Ceftiofur
D FOX AZI CHL AXO AUG2 CIP GEN NAL XNL SXT AMP STR FIS Sulfisoxazole
4 1 2 8 8/4 0.25 2 2 0.25 2/38 4 2
SXT Trimethoprim / Sulfamethoxazole
AMP Ampicillin
E FOX AZI TET AXO AUG2 CIP GEN NAL XNL SXT AMP NEG STR Streptomycin
2 0.5 32 4 4/2 0.12 1 1 0.12 1/19 2 NEG Negative control
POS Positive control
FOX AZI TET AXO AUG2 CIP GEN NAL FIS SXT AMP POS
F 1 0.25 16 2 2/1 0.06 0.5 0.5 256 0.5/9.5 1
G FOX AZI TET AXO AUG2 CIP GEN XNL FIS SXT STR POS
0.5 0.12 8 1 1/0.5 0.03 0.25 8 128 0.25/4.75 64
AZI CHL TET AXO CIP CIP NAL XNL FIS SXT STR POS
H 16 32 4 0.5 4 0.015 32 4 64 0.12/2.38 32
†
Not available in Europe.
47
Surveillance
Antimicrobial susceptibility plate for testing Salmonella and Escherichia coli isolates as part of The National Antimicrobial
Resistance Monitoring System (NARMS) program in the United States
Inoculate plate with Seal Sensititre plate and Automatically read with
Put 3-5 colonies into H20 o
50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
to measure a 0.5 McFarland
the suspension using a non-CO2 incubator or or manually read with
using the Nephelometer, Mix
the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
10 μl of suspension into MHB
Multi-Channel Pipette for 18 hours Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A FOX AZI CHL AXO AXO CIP GEN NAL MERO FIS AMP STR
32 16 16 64 0.25 2 16 16 1 32 32 16 AUG2 Amoxicillin / Clavulanic acid 2:1 ratio
AMP Ampicillin
AZI Azithromycin
B FOX AZI CHL AXO AUG2 CIP GEN NAL MERO FIS AMP STR FOX Cefoxitin
16 8 8 32 32/16 1 8 8 0.5 16 16 8 AXO Ceftriaxone
CHL Chloramphenicol
CIP Ciprofloxacin
C FOX AZI CHL AXO AUG2 CIP GEN NAL MERO SXT AMI STR
8 4 4 16 16/8 0.5 4 4 0.25 4/76 8 4 GEN Gentamicin
MERO Meropenem
NAL Nalidixic Acid
D FOX AZI CHL AXO AUG2 CIP GEN NAL MERO SXT AMP STR STR Streptomycin
4 2 2 8 8/4 0.25 2 2 0.12 2/38 4 2
FIS Sulfisoxazole
TET Tetracycline
E FOX AZI TET AXO AUG2 CIP GEN NAL MERO SXT AMP NEG SXT Trimethoprim / Sulfamethoxazole
2 1 32 4 4/2 0.12 1 1 0.06 1/19 2 NEG Negative control
POS Positive control
FOX AZI TET AXO AUG2 CIP GEN NAL FIS SXT AMP POS
F 1 0.5 16 2 2/1 0.06 0.5 0.5 256 0.5/9.5 1
G FOX AZI TET AXO AUG2 CIP GEN MERO FIS SXT STR POS
0.5 0.25 8 1 1/0.5 0.03 0.25 4 128 0.25/4.75 64
AZI CHL TET AXO CIP CIP NAL MERO FIS SXT STR POS
H 32 32 4 0.5 4 0.015 32 2 64 0.12/2.38 32
†
Not available in Europe.
48
Surveillance
Antimicrobial susceptibility plate for testing Enterococcus isolates as part of the National Antimicrobial Resistance
Monitoring System (NARMS) program in the United States
Inoculate plate with Seal Sensititre plate and Automatically read with
Put 3-5 colonies into H20 o
50 μl volume per well of incubate at 34-36 C in ARIS 2X† or OptiRead
to measure a 0.5 McFarland
the suspension using a non-CO2 incubator or or manually read with
using the Nephelometer, Mix
the Sensititre AIM or Sensititre ARIS 2X† Sensititre Vizion or
10 μl of suspension into MHB
Multi-Channel Pipette for 18 hours* Sensititre Manual Viewbox
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A TGC TGC TGC TGC TGC TGC ERY ERY ERY ERY ERY ERY
0.015 0.03 0.06 0.12 0.25 0.5 0.25 0.5 1 2 4 8 TGC Tigecycline
TET Tetracycline
CHL Chloramphenicol
B TET TET TET TET TET TET CIP CIP CIP CIP CIP CIP DAP Daptomycin
1 2 4 8 16 32 0.12 0.25 0.5 1 2 4 STR Streptomycin
TYLT Tylosin tartarte
SYN Quinupristin / Dalfoprisitn
C CHL CHL CHL CHL CHL PEN PEN PEN PEN PEN PEN PEN
2 4 8 16 32 0.25 0.5 1 2 4 8 16 LZD Linezolid
NIT Nitrofurantoin
PEN Penicillin
D DAP DAP DAP DAP DAP DAP DAP VAN VAN VAN VAN VAN KAN Kanamycin
0.25 0.5 1 2 4 8 16 0.25 0.5 1 2 4
ERY Erythromycin
CIP Ciprofloxacin
E STR STR STR NIT NIT NIT NIT NIT NIT VAN VAN VAN VAN Vancomycin
512 1024 2048 2 4 8 16 32 64 8 16 32 LIN Linocomycin
GEN Gentamicin
NEG Negative control
TYLT TYLT TYLT TYLT TYLT TYLT TYLT TYLT GEN GEN GEN GEN
F 0.25 0.5 1 2 4 8 16 32 128 256 512 1024 POS Positive control
G SYN SYN SYN SYN SYN SYN SYN LIN LIN LIN LIN NEG
0.5 1 2 4 8 16 32 1 2 4 8
LZD LZD LZD LZD LZD KAN KAN KAN KAN POS POS POS
H 0.5 1 2 4 8 128 256 512 1024
*Linezolid and nitrofurantoin should be read manually at 18 hours and vancomycin should be read manually at 24 hours. †Not available in Europe.
49
Surveillance
Antimicrobial susceptibility plate for testing Enterococcus isolates as part of the National Antimicrobial Resistance
Monitoring System (NARMS) program in the United States
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A TGC TGC TGC TGC TGC TGC TET TET TET TET TET TET
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 TGC Tigecycline
DAP Daptomycin
ERY Erythromycin
B DAP DAP DAP DAP DAP DAP DAP LZD LZD LZD LZD LZD GEN Gentamicin
0.25 0.5 1 2 4 8 16 0.5 1 2 4 8 CIP Ciprofloxacin
VAN Vancomycin
AMP Ampicillin
C ERY ERY ERY ERY ERY ERY STR STR STR STR STR STR
0.25 0.5 1 2 4 8 64 128 256 512 1024 2048 SYN Quinupristin / Dalfopristin
CHL Chloramphenicol
TET Tetracycline
D GEN GEN GEN GEN GEN GEN GEN NIT NIT NIT NIT NIT STR Streptomycin
16 32 64 128 256 512 1024 2 4 8 16 32
LZD Linezolid
NIT Nitrofurantoin
E CIP CIP CIP CIP CIP CIP CIP CIP NIT NIT NIT NIT AVL Avilamycin
0.12 0.25 0.5 1 2 4 8 16 64 128 256 512 NEG Negative control
POS Positive control
VAN VAN VAN VAN VAN VAN VAN VAN AVL AVL AVL AVL
F 0.25 0.5 1 2 4 8 16 32 4 8 16 32
G AMP AMP AMP AMP SYN SYN SYN SYN SYN SYN SYN POS
0.25 0.5 1 2 0.5 1 2 4 8 16 32
AMP AMP AMP AMP CHL CHL CHL CHL CHL CHL POS NEG
H 4 8 16 32 2 4 8 16 32 64
*Linezolid and nitrofurantoin should be read manually at 18 hours and vancomycin should be read manually at 24 hours.
50
Surveillance
Sensititre EU Surveillance
Campylobacter EUCAMP2 Plate
Intended Use
Antimicrobial susceptibility plate for testing Campylobacter isolates as part of a surveillance program
Put 3-5 colonies into Inoculate plate with Seal Sensititre plate and
Sensititre MHB 5 ml to reach 50 μl volume per well of incubate in a microaerophillic Manually read with
a 0.5 McFarland Standard, the suspension using atmosphere* at 35-37ºC for Sensititre Vizion or
Mix 100 μl into Sensititre the Sensititre AIM or 48 hours or at 42ºC Sensititre Manual Viewbox
MHB w/ LHB Multi-Channel Pipette for 24 hours**
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A ERY CIP TET GEN NAL STR ERY CIP TET GEN NAL STR
128 16 64 16 64 16 128 16 64 16 64 16 ERY Erythromycin
CIP Ciprofloxacin
TET Tetracycline
B ERY CIP TET GEN NAL STR ERY CIP TET GEN NAL STR GEN Gentamicin
64 8 32 8 32 8 64 8 32 8 32 8 NAL Nalidixic Acid
STR Streptomycin
ERY CIP TET GEN NAL STR ERY CIP TET GEN NAL STR POS Positive control
C
32 4 16 4 16 4 32 4 16 4 16 4
D ERY CIP TET GEN NAL STR ERY CIP TET GEN NAL STR
16 2 8 2 8 2 16 2 8 2 8 2
E ERY CIP TET GEN NAL STR ERY CIP TET GEN NAL STR
8 1 4 1 4 1 8 1 4 1 4 1
ERY CIP TET GEN NAL STR ERY CIP TET GEN NAL STR
F 4 0.5 2 0.5 2 0.5 4 0.5 2 0.5 2 0.5
G ERY CIP TET GEN NAL STR ERY CIP TET GEN NAL STR
2 0.25 1 0.25 1 0.25 2 0.25 1 0.25 1 0.25
ERY CIP TET GEN POS POS ERY CIP TET GEN POS POS
H 1 0.12 0.5 0.12 1 0.12 0.5 0.12
*85% N 2, 10% CO 2, 5% O 2. **Do not stack plates more than four high.
51
Surveillance
Intended Use
Antimicrobial susceptibility plate for testing Campylobacter isolates as part of a surveillance program
Put 3-5 colonies into Inoculate plate with Seal Sensititre plate and
Sensititre MHB 5 ml to reach 50 μl volume per well of incubate in a microaerophillic Manually read with
a 0.5 McFarland Standard, the suspension using atmosphere* at 35-37ºC for Sensititre Vizion or
Mix 100 μl into Sensititre the Sensititre AIM or 48 hours or at 42ºC Sensititre Manual Viewbox
MHB w/ LHB Multi-Channel Pipette for 24 hours**
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A AZI AZI AZI AZI AZI AZI AZI AZI AZI AZI AZI AZI
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 AZI Azithromycin
CIP Ciprofloxacin
ERY Erythromycin
B AZI CIP CIP CIP CIP CIP CIP CIP CIP CIP CIP CIP TET Tetracycline
64 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 FFN Florfenicol
NAL Nalidixic Acid
TEL Telithromycin
C CIP CIP ERY ERY ERY ERY ERY ERY ERY ERY ERY ERY
32 64 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 CLI Clindamycin
GEN Gentamicin
POS Positive control
D ERY ERY GEN GEN GEN GEN GEN GEN GEN GEN GEN TET
32 64 0.12 0.25 0.5 1 2 4 8 16 32 0.06
E TET TET TET TET TET TET TET TET TET TET FFN FFN
0.12 0.25 0.5 1 2 4 8 16 32 64 0.03 0.06
FFN FFN FFN FFN FFN FFN FFN FFN FFN FFN NAL NAL
F 0.12 0.25 0.5 1 2 4 8 16 32 64 4 8
G NAL NAL NAL TEL TEL TEL TEL TEL TEL TEL TEL TEL
16 32 64 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4
TEL CLI CLI CLI CLI CLI CLI CLI CLI CLI CLI POS
H 8 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16
*85% N 2, 10% CO 2, 5% O 2. **Do not stack plates more than four high.
52
Surveillance
Sensititre EU Surveillance
Staphylococcus EUST Plate
Intended Use
Antimicrobial susceptibility plate for testing Staphylococcus isolates as part of a surveillance program
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A CLI CLI CLI CLI CLI CLI ERY ERY ERY ERY ERY ERY
0.12 0.25 0.5 1 2 4 0.25 0.5 1 2 4 8 CLI Clindamycin
TET Tetracycline
RIF Rifampin
B TET TET TET TET TET TET CIP CIP CIP CIP CIP CIP STR Streptomycin
0.5 1 2 4 8 16 0.25 0.5 1 2 4 8 FUS Fusidate
PEN Penicillin
CHL Chloramphenicol
C RIF RIF RIF RIF RIF RIF FOX FOX FOX FOX FOX FOX
0.016 0.03 0.06 0.12 0.25 0.5 0.5 1 2 4 8 16 KAN Kanamycin
TIA Tiamulin
SYN Quinupristin / Dalfopristin
D STR STR STR STR TIA TIA TIA TIA LZD LZD LZD LZD VAN Vancomycin
4 8 16 32 0.5 1 2 4 1 2 4 8
GEN Gentamicin
TMP Trimethoprim
E FUS FUS FUS FUS SYN SYN SYN SYN MUP MUP MUP MUP ERY Erythromycin
0.5 1 2 4 0.5 1 2 4 0.5 1 2 256 CIP Ciprofloxacin
FOX Cefoxitin
LZD Linezolid
PEN PEN PEN PEN PEN VAN VAN VAN VAN VAN SMX SMX
F 0.12 0.25 0.5 1 2 1 2 4 8 16 64 128 MUP Mupirocin
SMX Sulfamethoxazole
NEG Negative control
G CHL CHL CHL CHL CHL GEN GEN GEN GEN GEN SMX SMX POS Positive control
4 8 16 32 64 1 2 4 8 16 256 512
KAN KAN KAN KAN KAN TMP TMP TMP TMP TMP NEG POS
H 4 8 16 32 64 2 4 8 16 32
*Incubate for 24 hours to ensure detection of oxacillin-resistant Staphylococcus and vancomycin-resistant Enterococcus spp.
53
Surveillance
Sensititre EU Surveillance
Enterococcus EUVENC Plate
Intended Use
Antimicrobial susceptibility plate for testing Enterococcus isolates as part of a surveillance program
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A VAN TEI SYN TET DAP CIP ERY TGC LZD GEN AMP CHL
128 64 64 128 32 16 128 4 64 1024 64 128 VAN Vancomycin
TEI Teicoplanin
SYN Quinupristin / Dalfopristin
B VAN TEI SYN TET DAP CIP ERY TGC LZD GEN AMP CHL TET Tetracycline
64 32 32 64 16 8 64 2 32 512 32 64 DAP Daptomycin
CIP Ciprofloxacin
ERY Erythromycin
C VAN TEI SYN TET DAP CIP ERY TGC LZD GEN AMP CHL
32 16 16 32 8 4 32 1 16 256 16 32 TGC Tigecycline
LZD Linezolid
GEN Gentamicin
D VAN TEI SYN TET DAP CIP ERY TGC LZD GEN AMP CHL AMP Ampicillin
16 8 8 16 4 2 16 0.5 8 128 8 16
CHL Chloramphenicol
POS Positive control
E VAN TEI SYN TET DAP CIP ERY TGC LZD GEN AMP CHL
8 4 4 8 2 1 8 0.25 4 64 4 8
VAN TEI SYN TET DAP CIP ERY TGC LZD GEN AMP CHL
F 4 2 2 4 1 0.5 4 0.12 2 32 2 4
G VAN TEI SYN TET DAP CIP ERY TGC LZD GEN AMP POS
2 1 1 2 0.5 0.25 2 0.06 1 16 1
VAN TEI SYN TET DAP CIP ERY TGC LZD GEN AMP POS
H 1 0.5 0.5 1 0.25 0.12 1 0.03 0.5 8 0.5
*Incubate for 24 hours to ensure detection of oxacillin-resistant Staphylococcus and vancomycin-resistant Enterococcus spp.
54
Surveillance
Sensititre EU Surveillance
Salmonella/E. coli EUVSEC Plate
Intended Use
Antimicrobial susceptibility plate for testing Salmonella and Escheria coli isolates as part of a surveillance program
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A SMX TMP CIP TET MERO AZI NAL CHL TGC COL AMP GEN
1024 32 8 64 16 64 128 128 8 16 64 32 SMX Sulfamethoxazole
TMP Trimethoprim
CIP Ciprofloxacin
B SMX TMP CIP TET MERO AZI NAL CHL TGC COL AMP GEN TET Tetracycline
512 16 4 32 8 32 64 64 4 8 32 16 MERO Meropenem
AZI Azithromycin
NAL Nalidixic Acid
C SMX TMP CIP TET MERO AZI NAL CHL TGC COL AMP GEN
256 8 2 16 4 16 32 32 2 4 16 8 FOT Cefotaxime
CHL Chloramphenicol
TGC Tigecycline
D SMX TMP CIP TET MERO AZI NAL CHL TGC COL AMP GEN TAZ Ceftazidime
128 4 1 8 2 8 16 16 1 2 8 4
COL Colistin
AMP Ampicillin
E SMX TMP CIP TET MERO AZI NAL CHL TGC COL AMP GEN GEN Gentamicin
64 2 0.5 4 1 4 8 8 0.5 1 4 2 POS Positive control
SMX TMP CIP TET MERO AZI NAL FOT TGC TAZ AMP GEN
F 32 1 0.25 2 0.5 2 4 1 0.25 2 2 1
G SMX TMP CIP CIP MERO MERO FOT FOT TAZ TAZ AMP GEN
16 0.5 0.12 0.03 0.25 0.06 4 0.5 8 1 1 0.5
SMX TMP CIP CIP MERO MERO FOT FOT TAZ TAZ POS POS
H 8 0.25 0.06 0.015 0.12 0.03 2 0.25 4 0.5
55
Surveillance
Antimicrobial susceptibility plate for testing ESBL isolates as part of a surveillance program
1 2 3 4 5 6 7 8 9 10 11 12 Antimicrobics
A FOX FOX FOX FOX FOX FOX FOX FOX FOT FOT FOT TRM
0.5 1 2 4 8 16 32 64 0.25 0.5 1 128 FOX Cefoxitin
ETP Ertapenem
IMI Imipenem
B ETP ETP ETP ETP ETP ETP ETP ETP FOT FOT FOT TRM MERO Meropenem
0.015 0.03 0.06 0.12 0.25 0.5 1 2 2 4 8 64 TAZ Ceftazidime
FEP Cefepime
F/C Cefotaxime / Clavulanic acid
C IMI IMI IMI IMI IMI IMI IMI IMI FOT FOT FOT TRM
0.12 0.25 0.5 1 2 4 8 16 16 32 64 32 T/C Ceftazidime / Clavulanic acid
FOT Cefotaxime
TRM Temocillin
D MERO MERO MERO MERO MERO MERO MERO MERO MERO MERO TRM TRM POS Positive control
0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 2 16
E TAZ TAZ TAZ TAZ TAZ TAZ TAZ TAZ TAZ TAZ TRM TRM
0.25 0.5 1 2 4 8 16 32 64 128 1 8
FEP FEP FEP FEP FEP FEP FEP FEP FEP FEP TRM TRM
F 0.06 0.12 0.25 0.5 1 2 4 8 16 32 0.5 4
G F/C F/C F/C F/C F/C F/C F/C F/C F/C F/C F/C POS
0.06/4 0.12/4 0.25/4 0.5/4 1/4 2/4 4/4 8/4 16/4 32/4 64/4
T/C T/C T/C T/C T/C T/C T/C T/C T/C T/C T/C POS
H 0.12/4 0.25/4 0.5/4 1/4 2/4 4/4 8/4 16/4 32/4 64/4 128/4
56
QUALITY CONTROL
Thermo Scientific™ Culti-Loops™ enable quick and safe preparation of ATCC® cultures for QC testing.
They are ready-to-use bacteriological loops containing gel-stabilised micro-organisms. Each loop is
individually packaged in a foil pouch and each pack contains 5 loops.
Below is a list of Culti-Loops containing the recommended ATCC® Strains for the EUCAST and CLSI
test methods:
The ATCC Licensed Derivative Emblem, the ATCC Licensed Derivative word mark and the ATCC catalog marks are trademarks of ATCC. Remel Inc. is licensed to use these trademarks
and to sell products derived from ATCC ® cultures. The identity, purity, and authenticity of the Licensed Products are exclusively the responsibility of Remel Inc., and not ATCC.
The European Committee on Antimicrobial Susceptibility Testing. Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST.
Version 8.0, 2018. www.eucast.org
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100. Clinical and Laboratory Standards
Institute, 950 West Valley Road, Suit 2500, Wayne, Pennsylvania 19087 USA, 2017
57 57
CUSTOM CAPABILITIES
Though the size and workload demands of microbiology laboratories vary, a challenge
for each remains in expediting susceptibility testing to facilitate more informed treatment
decisions, and improve patient care.
58
CUSTOM CAPABILITIES
It’s not enough to have access to one of the widest, most up-to-date selections of antimicrobials if you
can’t specifically address the needs of your formulary or patient population. With dilution ranges of
your choice and the ability to update formats conveniently, Sensititre Custom Plate capabilities allow
you to create the ultimate test program with the flexibility to address the challenges of each individual
microbiology laboratory.
Offering tailor-made AST with the latest antimicrobials, our custom capabilities lead to relevant results
that are based on real-time resistance trends and local epidemiology, allowing you to improve clinical
outcomes and effectively manage resistance in your institution.
Every custom plate comes complete with the required Thermo Scientific™
Sensititre™ SWIN™ Software script specific to your design to ensure
Delivery results are reported with correct interpretive criteria. Plates may also
be read manually subject to configuration
59 59
CUSTOMER SERVICE AND INSTALLATION
60
Glossary
US EU ROW
Application Plate Application Plate Application Plate
GN4F GN4F GN4F
GN6F GN6F GN6F
GNX2F GNX2F GNX2F
GNX3F GNX3F GNX3F
DELAXN DKMGN GPALL1F
MEROVAB EURGNCOL STP6F
GPALL1F GPALL1F Human HPB1
GPALL3F GPALL3F YO2IVD
FDANDPF Human EUSTAPF YO3IVD
Human
FDANDSF STP6F YO10
STP6F HPB1 MYCOTBI
HPB1 YO2IVD RAPMYCOI
YO2IVD YO3IVD SLOMYCOI
YO3IVD YO10 AVIAN1F
YO9 MYCOTBI BOPO6F
MYCOTB RAPMYCOI COMPGP1F
RAPMYCO SLOMYCOI COMPGN1F
Vet
SLOMYCO AVIAN1F EQUIN1F
AVIAN1F BOPO6F CMV1AMAF
BOPO6F COMPGP1F CMV1BURF
BOPO7F COMPGN1F JOEYE2
Vet
COMPGP1F EQUIN1F CMV3AGNF
Vet COMPGN1F CMV1AMAF CMV4AGNF
Surveillance
EQUIN1F CMV1BURF CMV3AGPF
CMV1AMAF JOEYE2 CMV4AGP
CMV1BURF CMV3AGNF
JOEYE2 CMV4AGNF
CMV3AGNF CMV3AGPF
CMV4AGNF CMV4AGP
Surveillance
CMV3AGPF Surveillance EUCAMP2
CMV4AGP EUST
EUVENC
EUVSEC
EUVSEC2
61 61
Find out more at thermofisher.com/AST
©2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are property of Thermo Fisher Scientific and its subsidiaries
unless otherwise specified.
Contact Information:
[email protected] LT2379A
USA +800 255 6730 991-345
International +44(0) 1256 841144 November 2018